The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions

2005/12/21 by R. Scott Obach, Robert L. Walsky, Karthik Venkatakrishnan +3 · 28 citations
Pharmacology, Toxicology and Pharmaceutics · Medicine · Computer Science · #Pharmacogenetics and Drug Metabolism #Drug Transport and Resistance Mechanisms #Computational Drug Discovery Methods

paper · doi:10.1124/jpet.105.093229

Cited by

• Prediction of Human Drug Clearance by Multiple Metabolic Pathways: Integration of Hepatic and Intestinal Microsomal and Cytosolic Data
• Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions
• A Combined Model for Predicting CYP3A4 Clinical Net Drug-Drug Interaction Based on CYP3A4 Inhibition, Inactivation, and Induction Determined in Vitro
• In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. [europepmc]
• Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (+/-)-suprofen: a comparison of kinetics and probe substrate selection. [europepmc]
• Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database. [europepmc]
• Predicting drug-drug interactions: an FDA perspective. [europepmc]
• Cooperative properties of cytochromes P450. [europepmc]
• Membrane transporters in drug development. [europepmc]
• Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. [europepmc]
• Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51). [europepmc]
• In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. [europepmc]
• A novel type of allosteric regulation: functional cooperativity in monomeric proteins. [europepmc]
• Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data. [europepmc]
• Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport. [europepmc]
• In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates. [europepmc]
• In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. [europepmc]
• The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. [europepmc]
• The use of isomeric testosterone dimers to explore allosteric effects in substrate binding to cytochrome P450 CYP3A4. [europepmc]
• Molecular tweezers for lysine and arginine - powerful inhibitors of pathologic protein aggregation. [europepmc]
• Drug Metabolism in Preclinical Drug Development: A Survey of the Discovery Process, Toxicology, and Computational Tools. [europepmc]
• Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A. [europepmc]
• Effects and Mechanism of Nano-Copper Exposure on Hepatic Cytochrome P450 Enzymes in Rats. [europepmc]
• Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids. [europepmc]
• Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions. [europepmc]
• Improving natural product research translation: From source to clinical trial. [europepmc]
• Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. [europepmc]
• Kratom Alkaloids: Interactions With Enzymes, Receptors, and Cellular Barriers. [europepmc]